Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InspireMDSTU:II2 +4.20%47 3-Year EBITDA Growth Rate is 31.30% as of Mar. 2026, which is 47% below its 10-year median of 58.65. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.50 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, InspireMD ranks better than 78.18% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 31.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of InspireMD was 88.10% per year. The lowest was 26.30% per year. And the median was 58.65% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
InspireMD 3-Year EBITDA Growth Rate Related Terms
STU:II2 vs TELA, BDMD, PAVM: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, InspireMD's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where InspireMD's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 31.30% mean?
InspireMD (STU:II2) has a 3-Year EBITDA Growth Rate of 31.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for InspireMD and its competitors. This is 47% below median its historical median of 58.65. Over the past decade, InspireMD's 3-Year EBITDA Growth Rate has ranged from 26.30 to 88.10. According to the industry distribution chart, InspireMD ranks #151 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 21.8%.
Is InspireMD's 3-Year EBITDA Growth Rate too high?
InspireMD's current 3-Year EBITDA Growth Rate of 31.30% is 47% below median its 10-year median of 58.65. Over the past 10 years, this metric has ranged from a low of 26.30 to a high of 88.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. InspireMD's value of 31.30% is 281.7% above this industry median. Based on the distribution chart, InspireMD ranks #151 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's 3-Year EBITDA Growth Rate compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #151 out of 692 companies for 3-Year EBITDA Growth Rate. This places InspireMD in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. InspireMD's value of 31.30% is 281.7% above this benchmark. Historically, InspireMD's own 3-Year EBITDA Growth Rate has ranged from 26.30 to 88.10 over the past decade. While the company's 10-year median is 58.65 vs. the industry median of 8.20, InspireMD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InspireMD's current 3-Year EBITDA Growth Rate of 31.30% is 281.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for InspireMD and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current 3-Year EBITDA Growth Rate is 31.30%, which is 47% below median its own 10-year median of 58.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.50, compared to a current price of €0.62 — trading 58.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 31.30%, which is 47% below median its 10-year median of 58.65 and 281.7% above the Medical Devices & Instruments industry median of 8.20. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For InspireMD (STU:II2), the current 3-Year EBITDA Growth Rate is 31.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.62 is trading 58.7% below its estimated GF Value™ of €1.50.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
3-Year EBITDA Growth Rate: 31.30% (47% below median its 10-year median of 58.65)
GF Value™: €1.50 vs. price of €0.62 (58.7% below fair value)
Industry Position: 281.7% above the Medical Devices & Instruments median (#151 of 692)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score
Get the complete analysis for STU:II2
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 
